UY31603A1 - Derivados de ftalazinona - Google Patents

Derivados de ftalazinona

Info

Publication number
UY31603A1
UY31603A1 UY031603A UY31603A UY31603A1 UY 31603 A1 UY31603 A1 UY 31603A1 UY 031603 A UY031603 A UY 031603A UY 31603 A UY31603 A UY 31603A UY 31603 A1 UY31603 A1 UY 31603A1
Authority
UY
Uruguay
Prior art keywords
optionally substituted
alkyl
ftalazinona
derivatives
aromatic ring
Prior art date
Application number
UY031603A
Other languages
English (en)
Inventor
Kevin Blades
Carlos Fernandez Lence
Muhammad Hashim Javaid
David Alan Rudge
Sylvie Gomez
Morrison Barr Martin Niall
Marc Geoffrey Hummersone
Keith Allan Menear
Craig Anthony Roberts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40510546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31603(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31603A1 publication Critical patent/UY31603A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Abstract

Un compuesto de la fórmula (I): donde A y B juntos representan un anillo aromático fusionado opcionalmente sustituido; X e Y se seleccionan entre CH y CH, CF y CH, CH y CF y N y CH respectivamente; Rc se selecciona entre H, C1-4 alquilo; y R1 se selecciona entre C1-7 alquilo, C3-20 heterociclilo y C5-20 arilo, estando dichos grupos opcionalmente sustituidos; o Rc y R1 junto con los átomos de carbono y oxígeno a los cuales están unidos forman un grupo espiro-C5-7 heterocíclico que contiene oxígeno, que es un anillo aromático C5-7 opcionalmente sustituido.
UY031603A 2008-01-23 2009-01-21 Derivados de ftalazinona UY31603A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2290008P 2008-01-23 2008-01-23
US14241309P 2009-01-05 2009-01-05

Publications (1)

Publication Number Publication Date
UY31603A1 true UY31603A1 (es) 2009-08-31

Family

ID=40510546

Family Applications (1)

Application Number Title Priority Date Filing Date
UY031603A UY31603A1 (es) 2008-01-23 2009-01-21 Derivados de ftalazinona

Country Status (24)

Country Link
US (2) US8129380B2 (es)
EP (1) EP2231638A1 (es)
JP (1) JP2011510056A (es)
KR (1) KR20100116187A (es)
CN (1) CN101925595A (es)
AR (1) AR070221A1 (es)
AU (1) AU2009207498A1 (es)
BR (1) BRPI0906436A2 (es)
CA (1) CA2708175A1 (es)
CL (1) CL2009000133A1 (es)
CO (1) CO6290715A2 (es)
DO (1) DOP2010000219A (es)
EA (1) EA201070523A1 (es)
EC (1) ECSP10010349A (es)
IL (1) IL206026A0 (es)
MX (1) MX2010006364A (es)
NI (1) NI201000120A (es)
NZ (1) NZ585982A (es)
PE (1) PE20091335A1 (es)
SV (1) SV2010003625A (es)
TW (1) TW200936577A (es)
UY (1) UY31603A1 (es)
WO (1) WO2009093032A1 (es)
ZA (1) ZA201003752B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163681A (zh) * 2005-04-21 2008-04-16 日本新药株式会社 2,3-二氮杂萘酮衍生物及其医药品
GB0521373D0 (en) * 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
ATE548369T1 (de) * 2006-01-16 2012-03-15 Ube Industries Pyrrolopyridazinonverbindung als pde4 inhibitor
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
TW201114756A (en) 2009-07-15 2011-05-01 Astrazeneca Ab Phthalazinone compound
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102485721B (zh) * 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
US20140221314A1 (en) 2011-05-31 2014-08-07 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
AR088352A1 (es) * 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
CN102702108A (zh) * 2012-06-27 2012-10-03 上海大学 1,2-二氢酞嗪类化合物及其合成方法
CN102863393A (zh) * 2012-09-26 2013-01-09 上海大学 1,2-二氢酞嗪类化合物及其合成方法
WO2014085208A1 (en) * 2012-11-27 2014-06-05 Merck Sharp & Dohme Corp. 2-pyridylamino-4-nitrile-piperidinyl orexin receptor antagonists
DK2938598T3 (en) * 2012-12-31 2017-02-13 Cadila Healthcare Ltd Substituted phthalazine-1 (2H) -one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
EP2964226A4 (en) * 2013-03-08 2016-08-10 Merck Sharp & Dohme 2-pyridyloxy-4-ESTER-orexin receptor antagonists
BR112016001645B1 (pt) * 2013-07-31 2023-04-11 Merck Patent Gmbh Derivados de oxoquinazolinil-butanamida, seu uso, medicamentos
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
CN109415345B (zh) * 2016-06-29 2022-01-11 豪夫迈·罗氏有限公司 基于哒嗪酮的广谱抗流感抑制剂
EA201992215A1 (ru) 2017-03-20 2020-02-06 Форма Терапьютикс, Инк. Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr)
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
CA3129516A1 (en) * 2018-02-28 2019-09-06 The Trustees Of The University Of Pennsylvania Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
CN110577953B (zh) * 2018-06-11 2024-02-20 深圳华大生命科学研究院 基因突变体及其应用
CN108727338B (zh) * 2018-07-05 2020-12-15 福建医科大学 一种4-哌啶酮类化合物及其制备方法与应用
EP3852791A4 (en) 2018-09-19 2022-06-15 Forma Therapeutics, Inc. ACTIVATION OF PYRUVATE KINASE R
US20220031671A1 (en) 2018-09-19 2022-02-03 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
CN109748923A (zh) * 2019-01-31 2019-05-14 中国药科大学 含苯并[4,5]咪唑[1,2-a]吡嗪酮类衍生物及其制备方法与用途
JP2022532342A (ja) * 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
CA3145644A1 (en) 2019-07-19 2021-01-28 Astrazeneca Ab Parp1 inhibitors
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CA3176219A1 (en) 2020-04-21 2021-10-28 Kunhee LEE Crystalline forms of phthalazinone compound
CN112624981B (zh) * 2021-03-09 2021-05-25 南京桦冠生物技术有限公司 一种2-氟-5-[(4-氧代-3h-2,3-二氮杂萘基)甲基]苯甲酸的制备方法
IL306010A (en) 2021-03-23 2023-11-01 Nuvation Bio Inc Anticancer compounds against the nuclear hormone receptor
CN115197211A (zh) 2021-04-01 2022-10-18 药捷安康(南京)科技股份有限公司 磷酸二酯酶抑制剂的制备方法
WO2023020457A1 (en) * 2021-08-17 2023-02-23 InventisBio Co., Ltd. Pyridazinone or pyridinone compounds, preparation methods and uses thereof

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB721286A (en) 1951-02-16 1955-01-05 Smith Kline & French Internat Improvements in or relating to the preparation of tetrahydroisoquinolone derivatives
DE2143745A1 (de) 1971-09-01 1973-03-08 Hoechst Ag 3,4-dihydro-2h-isochinolin-1-thione und verfahren zu ihrer herstellung
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
FR2262513A1 (en) 1974-03-01 1975-09-26 Delalande Sa 3,4,5-Triphenyl-delta-1,2,4-oxadiazolines - with bronchodilator, anti-cholinergic, hypertensive, analgesic and sedative activity
JPS54156526A (en) 1978-05-31 1979-12-10 Asahi Chemical Ind Dry picture forming material
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
JPS58164577A (ja) 1982-03-24 1983-09-29 Taiho Yakuhin Kogyo Kk ４―ベンジル―１―（２ｈ）イソキノロン誘導体
US4665181A (en) 1984-05-17 1987-05-12 Pennwalt Corporation Anti-inflammatory phthalazinones
US5041653A (en) 1985-05-03 1991-08-20 Sri International Substituted benzamide radiosensitizers
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US5032617A (en) 1985-05-03 1991-07-16 Sri International Substituted benzamide radiosensitizers
ATE60598T1 (de) 1985-11-11 1991-02-15 Asta Pharma Ag 4-benzyl-1-(2h)-phthalazinon-derivate.
GB8610018D0 (en) 1986-04-24 1986-05-29 Fujisawa Pharmaceutical Co Phthalazine derivatives
DE3640641A1 (de) 1986-11-28 1988-07-14 Thomae Gmbh Dr K Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3813531A1 (de) 1987-05-02 1988-11-10 Asta Pharma Ag Neue 2-aminoalkyl-4-benzyl-1-(2h)-phthalazinon-derivate
EP0355750B1 (en) 1988-08-19 1995-01-25 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
EP0389995B1 (en) 1989-03-28 1995-05-31 Nisshin Flour Milling Co., Ltd. Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension
DD287032A5 (de) 1989-07-28 1991-02-14 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung von 3-carbamoyl-4-aryl-1,2-di-hydro-isochinolin-1h-onen
GB9011833D0 (en) 1990-05-25 1990-07-18 Collins Mary K L Inhibition of viral infection
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
WO1993014086A1 (en) 1992-01-17 1993-07-22 Syntex (U.S.A.) Inc. Substituted 1-isoquinolone derivatives as angiotensin ii antagonists
CZ199593A3 (en) 1992-10-02 1994-04-13 Asta Medica Ag Phthalazinone derivatives exhibiting anti-arrhythmic and analgesic activity and eliminating resistance to a plurality of medicaments (mdr)
AU5455194A (en) 1992-11-02 1994-05-24 Merck & Co., Inc. Substituted phthalazinones as nerotensin antagonists
EP0634404A1 (en) 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazin derivatives and their use as pesticides
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
US5648355A (en) 1994-02-09 1997-07-15 Kos Pharmaceutical, Inc. Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
PT705903E (pt) 1994-08-12 2001-11-30 Myriad Genetics Inc Mutacoes no gene de susceptibilidade para o cancro da mama e do ovario ligado a 17q
ATE209660T1 (de) 1994-08-12 2001-12-15 Myriad Genetics Inc 17q-verbundenes ovarial- und brustkrebs empfindlichkeitsgen
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
IL120264A0 (en) 1996-02-29 1997-06-10 Pfizer Method of reducing tissue damage associated with non-cardiac ischemia
CA2205757C (en) 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
US5888529A (en) 1997-03-28 1999-03-30 The Regents Of The University Of California Ileus treatment method
WO1998051307A1 (en) 1997-05-13 1998-11-19 Octamer, Inc. METHODS FOR TREATING INFLAMMATION, INFLAMMATORY DISEASES, ARTHRITIS AND STROKE USING pADPRT INHIBITORS
AU8784698A (en) 1997-08-15 1999-03-08 Johns Hopkins University, The Method of using selective parp inhibitors to prevent or treat neurotoxicity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6426415B1 (en) 1997-09-03 2002-07-30 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6291425B1 (en) 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
AU1407399A (en) 1997-11-14 1999-06-07 Eli Lilly And Company Treatment for alzheimer's disease
WO1999044612A1 (en) 1998-03-02 1999-09-10 Cocensys, Inc. Substituted quinazolines and analogs and the use thereof
FR2776291B1 (fr) 1998-03-18 2000-06-16 Pf Medicament Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
ITMI981671A1 (it) 1998-07-21 2000-01-21 Zambon Spa Derivati ftalazinici inibitori della fosfodisterasi 4
EP1140936B1 (en) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
AU3076700A (en) 1999-01-26 2000-08-18 Ono Pharmaceutical Co. Ltd. 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
US6465448B1 (en) 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
KR20010087401A (ko) 1999-09-28 2001-09-15 스타르크, 카르크 아제피노인돌 유도체, 그의 제법 및 용도
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
DE50112961D1 (de) 2000-02-01 2007-10-18 Abbott Gmbh & Co Kg Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
WO2001079184A1 (fr) 2000-04-18 2001-10-25 Sumitomo Pharmaceuticals Company, Limited Composes de piperazine substitues
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
WO2001087845A2 (en) 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
WO2001090077A1 (en) 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
IL155645A0 (en) 2000-10-30 2003-11-23 Kudos Pharm Ltd Phthalazinone derivatives
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2002220241A1 (en) 2000-12-01 2002-06-11 Iconix Pharmaceuticals, Inc. Parb inhibitors
WO2002068407A1 (fr) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Compose benzimidazole
US6664269B2 (en) 2001-05-08 2003-12-16 Maybridge Plc Isoquinolinone derivatives
WO2002094790A1 (fr) 2001-05-23 2002-11-28 Mitsubishi Pharma Corporation Compose heterocyclique condense et son utilisation medicale
WO2003007959A1 (en) 2001-07-16 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. Quinoxaline derivatives which have parp inhibitory action
AU2002358650A1 (en) 2001-12-14 2003-06-30 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo(4,5,1-ij)quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
AUPR975601A0 (en) 2001-12-24 2002-01-31 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivatives
WO2003057145A2 (en) 2001-12-31 2003-07-17 Guilford Pharmaceuticals Inc. SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
EP2281818A1 (en) 2002-02-19 2011-02-09 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
ES2357057T3 (es) 2002-04-30 2011-04-15 Kudos Pharmaceuticals Limited Derivados de ftalazinona.
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB2415430B (en) * 2003-03-12 2006-07-12 Kudos Pharm Ltd Phthalazinone derivatives
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
JP2008510783A (ja) * 2004-08-26 2008-04-10 クドス ファーマシューティカルズ リミテッド ４−ヘテロアリールメチル置換フタラジノン誘導体
JPWO2006137510A1 (ja) 2005-06-24 2009-01-22 小野薬品工業株式会社 脳血管障害時における出血低減剤
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
EP2032140A1 (en) * 2006-05-31 2009-03-11 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
HUE027641T2 (en) * 2006-12-28 2016-11-28 Abbvie Inc Poly (ADP-ribose) polymerase inhibitors
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
KR20100059950A (ko) * 2007-09-14 2010-06-04 아스트라제네카 아베 프탈라지논 유도체

Also Published As

Publication number Publication date
CO6290715A2 (es) 2011-06-20
PE20091335A1 (es) 2009-10-04
CA2708175A1 (en) 2009-07-30
AU2009207498A1 (en) 2009-07-30
US20090192156A1 (en) 2009-07-30
US8129380B2 (en) 2012-03-06
EP2231638A1 (en) 2010-09-29
WO2009093032A1 (en) 2009-07-30
MX2010006364A (es) 2010-07-05
JP2011510056A (ja) 2011-03-31
BRPI0906436A2 (pt) 2015-07-14
EA201070523A1 (ru) 2011-02-28
SV2010003625A (es) 2011-05-20
DOP2010000219A (es) 2010-08-15
ZA201003752B (en) 2011-03-30
US20120129855A1 (en) 2012-05-24
NZ585982A (en) 2011-12-22
KR20100116187A (ko) 2010-10-29
CL2009000133A1 (es) 2010-10-15
NI201000120A (es) 2011-03-23
TW200936577A (en) 2009-09-01
IL206026A0 (en) 2010-11-30
CN101925595A (zh) 2010-12-22
AR070221A1 (es) 2010-03-25
ECSP10010349A (es) 2010-08-31

Similar Documents

Publication Publication Date Title
CO6290715A2 (es) Derivados de ftalazinona
UY31014A1 (es) Derivados de ftalazinona
AR058124A1 (es) Derivados de ftalazinona como inhibidores de parp-1
AR105820A1 (es) Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
AR092568A1 (es) Derivados triciclicos de quinolinas y de quinoxalinas
PE20140961A1 (es) Inhibidores macrociclicos de serina proteasas de hepatitis c
AR040546A1 (es) Derivados de la 1-h- pirrolidin -2,4- diona espirociclicos, cis- alcoxisubstituidos
AR067613A1 (es) Inhibidores de adn-pk, uso y sintesis de los mismos
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
PE20130155A1 (es) Derivados de ariletinilo
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
EA200971100A1 (ru) Производные фталазинона в качестве ингибиторов поли(адф-рибоза)полимеразы (parp-1)
CY1120477T1 (el) Ενεργοποιητης του υποδοχεα που ενεργοποιειται απο πολλαπλασιαστες των υπεροξεισωματων
CO6290657A2 (es) Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica
NI201100181A (es) Análogos de isoxazol - 3 (2h ) -ona como agentes terapéuticos
AR076170A1 (es) Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
ATE495175T1 (de) Naphthyridinderivate als kaliumkanalmodulatoren
CO6270225A2 (es) Un compuesto novedoso de anillo fusionado que presenta actividad inhibitoria de faah
EA201390022A1 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов фосфодиэстераз (фдэ)
CR11220A (es) Derivados de pirimidina 934
CO6362013A2 (es) Derivados de rifamicina
ECSP10010431A (es) DERIVADOS DE 4-(2-AMINO-1-HIDROXIETIL)FENOL COMO AGONISTAS DEL RECEPTOR ADRENÉRGICO b2.
CO6321168A2 (es) Nuevos derivados de 2-amidotiadiazol
RS53903B1 (en) ETHINYL DERIVATIVES AS POSITIVE MGLUR5 MODULATORS
BR112012033690A2 (pt) sais de cálcio de compostos como agentes anti-inflamatórios, imunomodulares e antitroliferativos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20180823